Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Brunet

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 18, 2023
Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response: Real-life studyK Khelef, E Maubec, G Jeudy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2021
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data<sup>☆</sup>Y Di Filippo, S Dalle, L Mortier, et al.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|September 5, 2025
Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel)F Skowron, S Mouret, A Seigneurin, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 17